{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:05:54Z","timestamp":1789517154647,"version":"build-2803163510"},"reference-count":43,"publisher":"Elsevier BV","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.cca.2014.01.043","type":"journal-article","created":{"date-parts":[[2014,2,8]],"date-time":"2014-02-08T04:00:26Z","timestamp":1391832026000},"page":"148-153","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"special_numbering":"C","title":["PCSK9 gene mutations and low-density lipoprotein cholesterol"],"prefix":"10.1016","volume":"431","author":[{"given":"Na-Qiong","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1251-6074","authenticated-orcid":false,"given":"Jian-Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cca.2014.01.043_bb0005","doi-asserted-by":"crossref","first-page":"3143","DOI":"10.1161\/circ.106.25.3143","article-title":"Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report","volume":"106","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.cca.2014.01.043_bb0010","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1038\/nrcardio.2011.2","article-title":"Pharmacological strategies for lowering LDL cholesterol: statins and beyond","volume":"8","author":"Brautbar","year":"2011","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.cca.2014.01.043_bb0015","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.atherosclerosis.2011.04.018","article-title":"Clinical aspects of PCSK9","volume":"216","author":"Cariou","year":"2011","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cca.2014.01.043_bb0020","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.numecd.2011.06.002","article-title":"Proprotein convertase subtilisin\/kexin type 9 (PCSK9): from structure\u2013function relation to therapeutic inhibition","volume":"21","author":"Tibolla","year":"2011","journal-title":"Nutr Metab Cardiovasc Dis"},{"key":"10.1016\/j.cca.2014.01.043_bb0025","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.tem.2006.02.001","article-title":"PCSK9: a promising therapeutic target for dyslipidemias?","volume":"17","author":"Lambert","year":"2006","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.cca.2014.01.043_bb0030","doi-asserted-by":"crossref","first-page":"2537","DOI":"10.1210\/jc.2009-0141","article-title":"Genetic and metabolic determinants of plasma PCSK9 levels","volume":"94","author":"Lakoski","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.cca.2014.01.043_bb0035","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.tibs.2006.12.008","article-title":"Molecular biology of PCSK9: its role in LDL metabolism","volume":"32","author":"Horton","year":"2007","journal-title":"Trends Biochem Sci"},{"issue":"Suppl.","key":"10.1016\/j.cca.2014.01.043_bb0040","doi-asserted-by":"crossref","first-page":"S172","DOI":"10.1194\/jlr.R800091-JLR200","article-title":"PCSK9: a convertase that coordinates LDL catabolism","volume":"50","author":"Horton","year":"2009","journal-title":"J Lipid Res"},{"key":"10.1016\/j.cca.2014.01.043_bb0045","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/humu.20882","article-title":"Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease","volume":"30","author":"Abifadel","year":"2009","journal-title":"Hum Mutat"},{"key":"10.1016\/j.cca.2014.01.043_bb0050","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/ng1161","article-title":"Mutations in PCSK9 cause autosomal dominant hypercholesterolemia","volume":"34","author":"Abifadel","year":"2003","journal-title":"Nat Genet"},{"key":"10.1016\/j.cca.2014.01.043_bb0055","doi-asserted-by":"crossref","first-page":"7100","DOI":"10.1073\/pnas.0402133101","article-title":"Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype","volume":"101","author":"Maxwell","year":"2004","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cca.2014.01.043_bb0060","doi-asserted-by":"crossref","first-page":"50630","DOI":"10.1074\/jbc.M410077200","article-title":"Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin\/kexin type 9a in mouse liver","volume":"279","author":"Park","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cca.2014.01.043_bb0065","doi-asserted-by":"crossref","first-page":"2069","DOI":"10.1073\/pnas.0409736102","article-title":"Overexpression of PCSK9 accelerates the degradation of the LDLR in a post-endoplasmic reticulum compartment","volume":"102","author":"Maxwell","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cca.2014.01.043_bb0070","doi-asserted-by":"crossref","first-page":"5374","DOI":"10.1073\/pnas.0501652102","article-title":"Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9","volume":"102","author":"Rashid","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.cca.2014.01.043_bb0075","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1373\/clinchem.2011.165191","article-title":"Novel loss-of-function PCSK9 variant is associated with low plasma LDL cholesterol in a French-Canadian family and with impaired processing and secretion in cell culture","volume":"57","author":"Mayne","year":"2011","journal-title":"Clin Chem"},{"key":"10.1016\/j.cca.2014.01.043_bb0080","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1038\/ng1509","article-title":"Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9","volume":"37","author":"Cohen","year":"2005","journal-title":"Nat Genet"},{"key":"10.1016\/j.cca.2014.01.043_bb0085","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/humu.20316","article-title":"The c.43_44insCTG variation in PCSK9 is associated with low plasma LDL-cholesterol in a Caucasian population","volume":"27","author":"Yue","year":"2006","journal-title":"Hum Mutat"},{"key":"10.1016\/j.cca.2014.01.043_bb0090","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1002\/humu.9383","article-title":"Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia","volume":"26","author":"Allard","year":"2005","journal-title":"Hum Mutat"},{"key":"10.1016\/j.cca.2014.01.043_bb0095","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1007\/s00439-003-1071-9","article-title":"A mutation in PCSK9 causing autosomal-dominant hypercholesterolemia in a Utah pedigree","volume":"114","author":"Timms","year":"2004","journal-title":"Hum Genet"},{"key":"10.1016\/j.cca.2014.01.043_bb0100","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1056\/NEJMoa054013","article-title":"Sequence variations in PCSK9, low LDL, and protection against coronary heart disease","volume":"354","author":"Cohen","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cca.2014.01.043_bb0105","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.atherosclerosis.2006.08.039","article-title":"The C679X mutation in PCSK9 is present and lowers blood cholesterol in a Southern African population","volume":"193","author":"Hooper","year":"2007","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cca.2014.01.043_bb0110","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1086\/500615","article-title":"A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol","volume":"78","author":"Kotowski","year":"2006","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.cca.2014.01.043_bb0115","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1161\/01.ATV.0000204337.81286.1c","article-title":"Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy","volume":"26","author":"Berge","year":"2006","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cca.2014.01.043_bb0120","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1042\/CS20070150","article-title":"The PCSK9 gene R46L variant is associated with lower plasma lipid levels and cardiovascular risk in healthy U.K. men","volume":"113","author":"Scartezini","year":"2007","journal-title":"Clin Sci"},{"key":"10.1016\/j.cca.2014.01.043_bb0125","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1056\/NEJMoa0706728","article-title":"Polymorphisms associated with cholesterol and risk of cardiovascular events","volume":"358","author":"Kathiresan","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.cca.2014.01.043_bb0130","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.amjcard.2007.02.057","article-title":"Relation of PCSK9 mutations to serum low-density lipoprotein cholesterol in childhood and adulthood (from The Bogalusa Heart Study)","volume":"100","author":"Hallman","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.cca.2014.01.043_bb0135","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.ymgme.2008.02.003","article-title":"Effect of protein convertase subtilisin\/kexin type 9 (PCSK9) 46L gene polymorphism on LDL cholesterol concentration in a Polish adult population","volume":"94","author":"Kostrzewa","year":"2008","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.cca.2014.01.043_bb0140","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.cca.2009.11.008","article-title":"Loss-of-function mutation R46L in the PCSK9 gene has little impact on the levels of total serum cholesterol in familial hypercholesterolemia heterozygotes","volume":"411","author":"Strom","year":"2010","journal-title":"Clin Chim Acta"},{"key":"10.1016\/j.cca.2014.01.043_bb0145","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1016\/j.jacc.2010.02.044","article-title":"PCSK9 R46L, low-density lipoprotein cholesterol levels, and risk of ischemic heart disease: 3 independent studies and meta-analyses","volume":"55","author":"Benn","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.cca.2014.01.043_bb0150","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1111\/j.1365-2796.2007.01915.x","article-title":"Characterization of novel mutations in the catalytic domain of the PCSK9 gene","volume":"263","author":"Cameron","year":"2008","journal-title":"J Int Med"},{"key":"10.1016\/j.cca.2014.01.043_bb0155","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.atherosclerosis.2009.11.018","article-title":"The E32K variant of PCSK9 exacerbates the phenotype of familial hypercholesterolaemia by increasing PCSK9 function and concentration in the circulation","volume":"210","author":"Noguchi","year":"2010","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.cca.2014.01.043_bb0160","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/1476-511X-10-5","article-title":"The proprotein convertase subtilisin\/kexin type 9 gene E670G polymorphism and serum lipid levels in the Guangxi Bai Ku Yao and Han populations","volume":"10","author":"Aung","year":"2011","journal-title":"Lipids Health Dis"},{"key":"10.1016\/j.cca.2014.01.043_bb0165","doi-asserted-by":"crossref","first-page":"124","DOI":"10.7150\/ijms.5296","article-title":"Proprotein convertase subtilisin\/kexin type 9 gene E670G polymorphism interacts with alcohol consumption to modulate serum lipid levels","volume":"10","author":"Aung","year":"2013","journal-title":"Int J Med Sci"},{"key":"10.1016\/j.cca.2014.01.043_bb0170","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1515\/CCLM.2009.032","article-title":"The PCSK9 gene E670G polymorphism affects low-density lipoprotein cholesterol levels but is not a risk factor for coronary artery disease in ethnic Chinese in Taiwan","volume":"47","author":"Hsu","year":"2009","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.cca.2014.01.043_bb0175","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1161\/01.ATV.0000133684.77013.88","article-title":"Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9","volume":"24","author":"Ouguerram","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cca.2014.01.043_bb0180","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1002\/clc.22014","article-title":"Design and rationale of the LAPLACE-TIMI 57 trial: a phase II, double-blind, placebo-controlled study of the efficacy and tolerability of a monoclonal antibody inhibitor of PCSK9 in subjects with hypercholesterolemia on background statin therapy","volume":"35","author":"Kohli","year":"2012","journal-title":"Clin Cardiol"},{"key":"10.1016\/j.cca.2014.01.043_bb0185","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/S0140-6736(12)61770-X","volume":"380","author":"Giugliano","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.cca.2014.01.043_bb0190","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1161\/CIRCULATIONAHA.112.144055","volume":"126","author":"Raal","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.cca.2014.01.043_bb0195","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1161\/CIRCULATIONAHA.113.001969","volume":"128","author":"Desai","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.cca.2014.01.043_bb0200","doi-asserted-by":"crossref","first-page":"11090","DOI":"10.1074\/jbc.M111.319764","article-title":"Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9","volume":"287","author":"Chaparro-Riggers","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.cca.2014.01.043_bb0205","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1161\/01.ATV.0000134621.14315.43","article-title":"Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia","volume":"24","author":"Dubuc","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.cca.2014.01.043_bb0210","first-page":"877","volume":"33","author":"Guo","year":"2013"},{"key":"10.1016\/j.cca.2014.01.043_bb0215","doi-asserted-by":"crossref","first-page":"519","DOI":"10.2217\/clp.13.55","article-title":"Rapid effects of different lipid-lowering drugs on Proprotein convertase subtilisin kexin\/type 9 in humans","volume":"8","author":"Liu","year":"2013","journal-title":"Clin Lipidol"}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898114000606?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898114000606?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,7]],"date-time":"2019-08-07T09:16:07Z","timestamp":1565169367000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898114000606"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":43,"alternative-id":["S0009898114000606"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2014.01.043","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"PCSK9 gene mutations and low-density lipoprotein cholesterol","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2014.01.043","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}